Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Life Sciences Industry Analysis

UpdatedAug 08, 2026
DataAggregated Company Financials
Companies22
  • 7D2.9%
  • 3M15.8%
  • 1Y22.8%
  • YTD22.6%

In the last week, the Life Sciences industry is up 5.0%, with Divi's Laboratories up 2.7%. This takes the industry's 12 month performance to a gain of 20%. Earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the Indian Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 08 Aug 2026₹3.8t₹371.0b₹48.7b40.1x78.2x10.3x
Mon, 06 Jul 2026₹3.3t₹361.8b₹46.4b40.8x72.1x9.2x
Wed, 03 Jun 2026₹3.2t₹362.2b₹46.4b36.9x69.5x8.9x
Fri, 01 May 2026₹3.2t₹351.5b₹45.9b32.5x69.2x9x
Sun, 29 Mar 2026₹2.9t₹350.2b₹46.2b28x61.9x8.2x
Tue, 24 Feb 2026₹3.0t₹350.2b₹46.2b27.8x64.1x8.5x
Thu, 22 Jan 2026₹2.9t₹342.6b₹48.4b29.8x59.6x8.4x
Sat, 20 Dec 2025₹3.1t₹342.6b₹48.4b31.7x65.1x9.2x
Mon, 17 Nov 2025₹3.1t₹338.4b₹47.8b36.3x65.8x9.3x
Wed, 15 Oct 2025₹3.2t₹331.4b₹45.5b42.7x71.2x9.8x
Fri, 12 Sep 2025₹3.2t₹331.4b₹45.5b48.4x69.4x9.5x
Sun, 10 Aug 2025₹3.1t₹327.2b₹44.2b51.4x69.7x9.4x
Tue, 08 Jul 2025₹2.9t₹300.7b₹37.2b44.7x79x9.8x
Thu, 05 Jun 2025₹2.8t₹299.9b₹37.2b46.4x76.4x9.5x
Sat, 03 May 2025₹2.6t₹289.3b₹30.9b46.2x84.1x9x
Mon, 31 Mar 2025₹2.6t₹287.4b₹30.8b45.3x84x9x
Wed, 26 Feb 2025₹2.5t₹287.4b₹30.8b47.8x80.4x8.6x
Fri, 24 Jan 2025₹2.5t₹269.1b₹30.1b50.4x83x9.3x
Sun, 22 Dec 2024₹2.5t₹269.1b₹30.1b49.9x82.6x9.2x
Tue, 19 Nov 2024₹2.3t₹254.1b₹28.8b47x80.1x9.1x
Thu, 17 Oct 2024₹2.5t₹247.6b₹26.3b52.8x94.1x10x
Sat, 14 Sep 2024₹2.3t₹247.6b₹26.3b51.9x88.5x9.4x
Mon, 12 Aug 2024₹1.9t₹206.4b₹24.8b35.8x77.5x9.3x
Wed, 10 Jul 2024₹1.8t₹202.0b₹23.9b37x74.8x8.9x
Fri, 07 Jun 2024₹1.7t₹195.5b₹21.5b32.7x78.8x8.7x
Sun, 05 May 2024₹1.5t₹167.8b₹18.7b29.9x78x8.7x
Tue, 02 Apr 2024₹1.4t₹168.5b₹18.6b27.7x73.4x8.1x
Thu, 29 Feb 2024₹1.4t₹168.5b₹18.6b32.3x73.2x8.1x
Sat, 27 Jan 2024₹1.4t₹166.8b₹18.9b30.5x72.1x8.2x
Mon, 25 Dec 2023₹1.4t₹155.9b₹18.1b21.3x75.1x8.7x
Wed, 22 Nov 2023₹1.4t₹155.9b₹18.1b23x75.9x8.8x
Fri, 20 Oct 2023₹1.3t₹156.2b₹19.8b26.9x67.7x8.6x
Sun, 17 Sep 2023₹1.4t₹154.7b₹19.7b25.4x73.1x9.3x
Tue, 15 Aug 2023₹1.4t₹160.1b₹23.2b23.6x60.5x8.7x
Price to Earnings Ratio

60.5x


Total Market Cap: ₹1.4tTotal Earnings: ₹23.2bTotal Revenue: ₹160.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Life Sciences Industry Price to Earnings3Y Average 74.8x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 74.7x.
  • The 3-year average PS ratio of 9.0x is lower than the industry's current PS ratio of 10.3x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 29% per year over the last three years.
  • Revenues for these companies have grown 32% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market1.27%
Healthcare0.61%
Life Sciences2.90%
Clinical Research and Equipment2.90%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹8.28k2.7%
+₹58.1b		39.9%PE75.1x
ANTHEM Anthem Biosciences₹841.003.9%
+₹17.9b		15.3%PE82.2x
SAILIFE Sai Life Sciences₹1.37k3.8%
+₹10.6b		64.9%PE80.1x
INDGN Indegene₹554.457.6%
+₹9.5b		-2.9%PE33.3x
SYNGENE Syngene International₹403.704.6%
+₹7.1b		-38.4%PE72.7x

Latest News

SAILIFE
₹1,365.20
Sai Life Sciences
7D
3.8%
1Y
64.9%
INNOVACAP
₹944.50
Innova Captab
7D
-3.1%
1Y
3.0%
BROOKS
₹60.01
Brooks Laboratories
7D
-1.6%
1Y
-61.0%
DIVISLAB
₹8,275.00
Divi's Laboratories
7D
2.7%
1Y
39.9%
Narrative Update • Aug 06

DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk

Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
TARSONS
₹312.30
Tarsons Products
7D
-0.7%
1Y
-12.4%
544184
₹141.65
Borosil Scientific
7D
-10.3%
1Y
-9.2%
530239
₹318.20
Suven Life Sciences
7D
3.6%
1Y
27.1%
INDGN
₹554.45
Indegene
7D
7.6%
1Y
-2.9%
Analysis Article • Aug 03

Indegene Limited (NSE:INDGN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

It's been a good week for Indegene Limited ( NSE:INDGN ) shareholders, because the company has just released its latest...
SYNGENE
₹403.70
Syngene International
7D
4.6%
1Y
-38.4%
ONESOURCE
₹1,576.00
OneSource Specialty Pharma
7D
-2.7%
1Y
-16.7%
Analysis Article • Jul 29

Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results

It's been a good week for OneSource Specialty Pharma Limited ( NSE:ONESOURCE ) shareholders, because the company has...
ANTHEM
₹841.00
Anthem Biosciences
7D
3.9%
1Y
15.3%
New Narrative • Jul 28

Capacity Expansion And Modalities Shift Will Support Stronger Long-Term Earnings Visibility

Catalysts About Anthem Biosciences Anthem Biosciences is a contract research, development and manufacturing organization with a large focus on CRDMO services and specialty ingredients across small molecules, peptides, fermentation and related modalities. What are the underlying business or industry changes driving this perspective?
540729
₹21.75
Vanta Bioscience
7D
-9.5%
1Y
-15.1%
FABTECH
₹148.63
Fabtech Technologies
7D
-0.6%
1Y
n/a
524394
₹650.70
Vimta Labs
7D
7.0%
1Y
2.5%
INFLUX
₹283.60
Influx Healthtech
7D
-4.3%
1Y
96.3%
AKUMS
₹697.45
Akums Drugs and Pharmaceuticals
7D
5.9%
1Y
45.2%
Narrative Update • Jul 03

AKUMS: Upcoming Board Actions And Dividends Will Support Future Earnings Expansion

Analysts have lifted the fair value estimate for Akums Drugs and Pharmaceuticals from ₹646.67 to ₹730.00, citing updated assumptions around revenue growth, profit margins, a slightly altered discount rate, and future P/E. What’s in the News for Akums Drugs and Pharmaceuticals A board meeting is scheduled on May 14, 2026 to consider and approve the quarter and full year results for the period ended March 31, 2026, and to consider dividend recommendations, the appointment of Mahajan & Aibara LLP as Internal Auditors for FY 2026-27, and other matters.